CFRX - ContraFect Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4800
-0.0070 (-1.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4870
Open0.4802
Bid0.4400 x 1300
Ask0.5800 x 800
Day's Range0.4800 - 0.4980
52 Week Range0.3550 - 2.9270
Volume491,743
Avg. Volume1,220,385
Market Cap38.117M
Beta (3Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.4950
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.17
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    YONKERS, N.Y., April 16, 2019 (GLOBE NEWSWIRE) --  ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that new data from its Phase 2 clinical trial of exebacase for the treatment of Staphylococcus aureus (Staph aureus) bacteremia including endocarditis was presented by Vance G. Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases, Duke University at a late-breaker session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The oral presentation, titled “Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics Alone In A First-in-Patient Phase 2 study,” reported new data demonstrating clinically meaningful increases in clinical responder rates in the pre-specified MRSA subgroup treated with exebacase, including a 22.9% higher responder rate at Day 7 and a 16.9% higher responder rate at Test of Cure, compared to MRSA patients treated with standard of care antibiotics (SOC) alone.

  • Benzinga12 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...

  • PR Newswire13 days ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire17 days ago

    ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that its manuscript titled “The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis” was published in the April edition of the peer-reviewed Antimicrobial Agents and Chemotherapy Journal of the American Society of Microbiology. The manuscript highlights in vitro activity of exebacase (CF-301) in human blood versus in a conventional testing medium (cation-adjusted Mueller-Hinton broth (caMHB)), in which exebacase exhibited markedly higher potency (32 to ≥100-fold) in human blood versus caMHB in three standard microbiologic testing formats and demonstrated synergistic interaction with two key human blood factors.

  • GlobeNewswire21 days ago

    ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that Dr. Vance Fowler will present new data from the Phase 2 study of exebacase (CF-301) at a late-breaker session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 13-16, 2019, in Amsterdam, Netherlands. ContraFect will also deliver an oral presentation of novel data from its lysin program targeting resistant Gram-negative (GN) pathogens, which demonstrate the potential for lysins to re-sensitize carbapenem-resistant Pseudomonas aeruginosa (P. aeruginosa) to both meropenem and imipenem.

  • GlobeNewswire23 days ago

    ContraFect Announces CEO Transition

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that Roger J. Pomerantz, MD, FACP has been appointed Chairman and Chief Executive Officer of ContraFect and will succeed Steven C. Gilman, Ph.D., who is retiring from his position as Chairman and CEO.

  • GlobeNewswirelast month

    ContraFect to Present at the Bacteriophage Therapy Summit

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development will participate in the inaugural Bacteriophage Therapy Summit (“Summit”) to be held from March 25-27, 2019 in Boston, MA. Dr. Cassino was invited to the Summit to present ContraFect’s journey to positive results in its Phase 2 clinical study with the first non-traditional antibacterial to progress to this stage of development.

  • Zacks Small Cap Researchlast month

    CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia…

    ContraFect Corp. (CFRX) is developing exebacase (CF-301), the company’s lead lysin product, for the treatment of bacteremia caused by Staphylococcus aureus infections. Exebacase has been tested in a number of pre-clinical studies and the company recently announced positive topline results from a Phase 2 study of exebacase (discussed below).

  • Associated Presslast month

    ContraFect: 4Q Earnings Snapshot

    On a per-share basis, the Yonkers, New York-based company said it had net income of 7 cents. Losses, adjusted for non-recurring gains, were 8 cents per share. The results exceeded Wall Street expectations. ...

  • GlobeNewswirelast month

    ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    YONKERS, N.Y., March 14, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated.

  • GlobeNewswirelast month

    ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in the 29th Annual Oppenheimer Healthcare Conference on Wednesday, March 20, 2019, at 3:55 PM ET in New York City. The focus will be on exebacase (CF-301), the Company's novel therapeutic candidate for Staph aureus bacteremia, including endocarditis, along with an update on the progress of its other pipeline assets. A live webcast of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com.

  • GlobeNewswire2 months ago

    ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company up to $6.94 million in non-dilutive funding to accelerate the development of its newly discovered and proprietary class of amurin peptides as potential therapeutics to treat serious and potentially life-threatening infections, including those caused by antibiotic-resistant Gram-negative ESKAPE pathogens. The company intends to progress these compounds as quickly as possible through hit-to-lead and optimization towards clinical development as potential treatments for pulmonary exacerbations of cystic fibrosis and hospital-acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP).

  • GlobeNewswire2 months ago

    Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX)

    LOS ANGELES, Feb. 25, 2019 -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of ContraFect Corporation (NASDAQ: CFRX) investors concerning the.

  • GlobeNewswire2 months ago

    ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Raymond Schuch, Ph.D., the Company’s Vice President of Research, was invited to give an oral presentation entitled, “Bacteriophage-Derived Lysins Engineered to Exert a Rapid and Potent Bactericidal Effect Against Pseudomonas aeruginosa,” at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine in Lucca, Italy. Following the meeting, the presentation materials will be available on the ContraFect website.

  • PR Newswire3 months ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • ACCESSWIRE3 months ago

    These 4 Healthcare Stocks Are Raising Expectations

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), LM Funding America Inc., (LMFA), CorMedix Inc (CRMD), and ContraFect Corp (CFRX) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • GlobeNewswire3 months ago

    ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company $2.3 million in additional funding over the course of the next two years. The Company will use the grant for the development of lysin therapeutics to treat serious, potentially life-threatening invasive infections caused by antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa), a virulent Gram-negative pathogen.

  • Zacks Small Cap Research3 months ago

    CFRX: Exebacase Improves Clinical Outcomes in Phase 2 Trial…

    On January 7, 2019, ContraFect Corp. (CFRX) announced topline results from the Phase 2 trial of exebacase (CF-301) in patients with bacteremia caused by Staphylococcus aureus, including those with endocarditis. This was an international, multicenter, randomized, double blind, placebo controlled trial with a superiority comparison between exebacase or placebo combined with the standard of care antibiotics.

  • GlobeNewswire4 months ago

    ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced positive topline results from its Phase 2 clinical trial of exebacase (CF-301) for the treatment of Staphylococcus aureus (Staph aureus) bacteremia including endocarditis. Overall, exebacase, used in addition to standard of care (SOC) antibiotics, achieved clinically meaningful improvement in the primary efficacy endpoint of clinical response at Day 14 as demonstrated by a 70.4% responder rate as compared to a 60.0% responder rate among patients treated with antibiotics alone.  Higher responder rates at Day 14 were also seen with exebacase compared to antibiotics alone in pre-specified exploratory analyses in methicillin-resistant Staph aureus (MRSA) patients (p=0.010) and in patients diagnosed with Staph aureus bacteremia alone (p=0.035) as well as in the subgroup of patients with Staph aureus bacteremia including right-sided endocarditis (p=0.028).

  • Is ContraFect Corp (CFRX) A Good Stock To Buy?
    Insider Monkey4 months ago

    Is ContraFect Corp (CFRX) A Good Stock To Buy?

    Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]

  • GlobeNewswire4 months ago

    ContraFect to Present at Biotech Showcase 2019

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., the Company’s Chief Medical Officer and Executive Vice President of Research and Development, will present a corporate overview at the Biotech Showcase on Tuesday, January 8, 2019, at 11:00 AM PT (2:00 PM ET) in San Francisco, CA. ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.

  • GlobeNewswire5 months ago

    ContraFect to Present at Piper Jaffray Health Care Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in a fireside chat at the Piper Jaffray Health Care Conference on Wednesday, November 28, 2018 at 9:00 AM ET in New York, NY. The focus will be on ContraFect's lead program, exebacase (CF-301), the Company's potential novel treatment for Staphylococcus aureus (Staph aureus) bacteremia, including endocarditis, along with an update on the progress of its other pipeline assets.

  • GlobeNewswire5 months ago

    Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zacks Small Cap Research5 months ago

    CFRX: Waiting on Data from Phase 2 Study of CF-301…

    In September 2018, ContraFect Corp. (CFRX) announced that the Phase 2 trial of CF-301 (exebacase) is fully enrolled. The trial is an international, multicenter, randomized, double blind, placebo controlled study with a superiority comparison between CF-301 or placebo combined with the standard of care antibiotics. The primary endpoint of the study will be early clinical response.

  • GlobeNewswire5 months ago

    ContraFect Appoints Michael Messinger as Chief Financial Officer

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the appointment of Michael Messinger as the Company’s Chief Financial Officer. Mr. Messinger previously served as the Company’s Senior Vice President of Finance. Prior to joining the Company in 2012, Mr. Messinger was Director of Finance at Lexicon Pharmaceuticals, where he was responsible for the financial management of Lexicon's partnership with Symphony Capital, in addition to fiscal coordination and project management concerning Lexicon's development programs.